Literature DB >> 12821611

Osteoporosis guidelines.

Edmund R Yendt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821611      PMCID: PMC161602     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

Review 1.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

2.  Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Authors:  C C Johnston; N H Bjarnason; F J Cohen; A Shah; R Lindsay; B H Mitlak; W Huster; M W Draper; K D Harper; H Heath; C Gennari; C Christiansen; C D Arnaud; P D Delmas
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

3.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 4.  Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.

Authors:  Ann Cranney; Peter Tugwell; Nicole Zytaruk; Vivian Robinson; Bruce Weaver; Jonathan Adachi; George Wells; Beverley Shea; Gordon Guyatt
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.